Comparison of Qualitative PCR and pp65 Antigenemia for the Diagnosis of CMV Infection in Hematopoietic Stem Cell Transplanted Patients

Authors
B. Khansarinejad 1
H. Soleimanjahi 1
A. Hamidieh 2
S. Mirab Samiee 3
M. Paryan 4
Y. Sanahmadi 5
S. Faghihzadeh 6
1 Department of Virology, Faculty of medical science, Tarbiat Modares University, Tehran, Iran
2 Hematology Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
3 Food and Drug Laboratory Research Center, Ministry of Health and Medical Education, Tehran, Iran
4 Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
5 MD, Day General Hospital Laboratory, Tehran, Iran
6 Department of Biostatistics, Faculty of medical science, Tarbiat Modares University, Tehran, Iran
Abstract
Objectives: Human cytomegalovirus (CMV) is a major life-threatening pathogen for hematopoietic stem cell transplant recipients. Specific tests are used for the diagnosis and monitoring of CMV infection in transplant patients. This study evaluates the performance of pp65 antigenemia and qualitative PCR assays for monitoring CMV in such patients.
Methods: We analyzed 179 clinical samples from 41 patients by using a validated home-brewed qualitative PCR and a commercial antigenemia assay. The obtained results were evaluated using quantitative real-time PCR as the gold standard.
Results: CMV was observed in 26.8% of samples analyzed by the antigenemia assay and in 42.6% of the samples by qualitative PCR. Among 179 clinical samples, 50.8% were negative and 21.2% were positive by both assays. On the other hand, 26.3% were only positive by qualitative PCR whereas 1.7% were positive by the antigenemia assay. A comparison of the results with real-time PCR showed that qualitative PCR has a higher sensitivity than the antigenemia assay (98.7% vs. 45.7%). The specificity of both assays was equal (96.8%). Quantitative results of the antigenemia assay showed good correlation with real-time PCR (r=0.715; p<0.001).
Conclusion: Both the qualitative PCR and antigenemia assays have special deficiencies for efficient diagnosis of CMV infection. Therefore, effective management of CMV infection in transplant patients requires the use of other sensitive quantitative methods such as qPCR.

Keywords

[1]     Ho M. The history of cytomegalovirus and its diseases. Med Microbiol Immunol 2008; 197(2): 65-73.
[2]     Ljungman P. Cytomegalovirus infections in transplant patients. Scand J Infect Dis Suppl 1996; 100: 59-63.
[3]     Falagas ME, Arbo M, Ruthazer R, Griffith JL, Werner BG, Rohrer R, Freeman R, Lewis WD, Snydman DR. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 1997; 63(11): 1595-601.
[4]     Legendre CM, Norman DJ, Keating MR, Maclaine GD, Grant DM. Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation. Transplantation 2000; 70(10): 1463-8.
[5]     Gleaves CA, Smith TF, Shuster EA, Pearson GR. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J Clin Microbiol 1984; 19(6): 917-9.
[6]     Mocarski ES, Shenk T, Pass RF. Cytomegaloviruses. In: Knipe DM, Howley PM, Griffin DE, editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2007; p: 2701-72.
[7]     Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80(5): 1358-64.
[8]     The TH, van der Bij W, van den Berg AP, van der Giessen M, Weits J, Sprenger HG, van Son WJ. Cytomegalovirus antigenemia. Rev Infect Dis 1990; 12 Suppl 7: S734-44.
[9]     Bordils A, Plumed JS, Ramos D, Beneyto I, Mascarós V, Molina JM, Cordoba J, García J, Crúz JM. Comparison of quantitative PCR and antigenemia in cytomegalovirus infection in renal transplant recipients. Transplant Proc 2005; 37(9): 3756-9.
[10]  Sanghavi SK, Abu-Elmagd K, Keightley MC, St George K, Lewandowski K, Boes SS, Bullotta A, Dare R, Lassak M, Husain S, Kwak EJ, Paterson DL, Rinaldo CR. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients. J Clin Virol 2008; 42(4): 335-42.
[11]  Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998; 11(3): 533-54.
[12]  Gerna G, Lilleri D, Baldanti F, Torsellini M, Giorgiani G, Zecca M, De Stefano P, Middeldorp J, Locatelli F, Revello MG. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood 2003; 101(12): 5053-60.
[13]  Hebart H, Wuchter P, Loeffler J, Gscheidle B, Hamprecht K, Sinzger C, Jahn G, Dietz K, Kanz L, Einsele H. Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant. Bone Marrow Transplant 2001; 28(2): 213-8.
[14]  Lilleri D, Baldanti F, Gatti M, Rovida F, Dossena L, De Grazia S, Torsellini M, Gerna G. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients. J Med Virol 2004; 73(3): 412-8.
[15]  Limaye AP, Bakthavatsalam R, Kim HW, Kuhr CS, Halldorson JB, Healey PJ, Boeckh M. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78(9): 1390-6.
[16]  Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113(23): 5711-9.
[17]  Kalpoe JS, Kroes AC, de Jong MD, Schinkel J, de Brouwer CS, Beersma MF, Claas EC. Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection. J Clin Microbiol 2004; 42(4): 1498-504.
[18]  Lilleri D, Gerna G, Furione M, Bernardo ME, Giorgiani G, Telli S, Baldanti F, Locatelli F. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia. Blood 2007; 110(7): 2757-60.
[19]  Boeckh M, Huang M, Ferrenberg J, Stevens-Ayers T, Stensland L, Nichols WG, Corey L. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004; 42(3): 1142-8.
[20]  Ghaffari SH, Obeidi N, Dehghan M, Alimoghaddam K, Gharehbaghian A, Ghavamzadeh A. Monitoring of cytomegalo-virus reactivation in bone marrow transplant recipients by real-time PCR. Pathol Oncol Res 2008; 14(4): 399-409.
[21]  Deback C, Fillet AM, Dhedin N, Barrou B, Varnous S, Najioullah F, Bricaire F, Agut H. Monitoring of human cytomegalovirus infection in immunosuppressed patients using real-time PCR on whole blood. J Clin Virol 2007; 40(3): 173-9.
Pathobiology Reserach
Volume 15, Issue 1
April 2012
Pages 13-22